https://www.bioworld.com/rss en-us Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732472 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732472-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Biopharma and med-tech companies raising money in public or private financings, including: Scribe. http://www.bioworld.com/articles/732426 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732426-financings-for-july-7-2026 The gene therapy specialist formerly known as EG427 has a new name and fresh momentum, after closing a €33 million (US$37.7 million) series C that will further advance clinical development of the lead program in chronic neuro-urology indications. http://www.bioworld.com/articles/732419 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732419-eg427-raises-377m-series-c-for-hsv-gene-therapy Bladder Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732473 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732473-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Biobot Surgical. http://www.bioworld.com/articles/732446 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732446-financings-for-july-7-2026 Biopharma and med-tech companies raising money in public or private financings, including: Abivax, Celea, Elicio, Tenon. http://www.bioworld.com/articles/732298 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732298-financings-for-july-6-2026 Biopharma and med-tech companies raising money in public or private financings, including: AB Science, Abivax, Alvotech, Artan, Bridgebio, Cadrenal, Creative Medical, Materna, Neurogene, Oryzon, Owlet, Pictor, Telum. http://www.bioworld.com/articles/732280 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732280-financings-for-july-2-2026 Biopharma financings across all categories totaled $59.76 billion on 567 deals in the first half (H1) of 2026, more than double H1 2025’s $29.53 billion across 501 transactions. http://www.bioworld.com/articles/732277 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732277-h1-2026-biopharma-financings-double-from-last-year-approach-pandemic-highs Blocks with upward arrows Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732271 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732271-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development. http://www.bioworld.com/articles/732358 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732358-artan-closes-seed-round-to-support-trna-platform Coins and seedling Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion. The figure reflects a sector that is holding well above the low years of 2022 and 2023. http://www.bioworld.com/articles/732392 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732392-follow-ons-lead-a-mixed-first-half-of-2026-for-med-tech-financing Global currency Biopharma and med-tech companies raising money in public or private financings, including: Aicuris, Alopexx, Beeline, Biodexa, Collplant, Epitome, Fibrobiologics, Flare, Nurexone, Nuvectis, Oblique, Pyxis, Smartbax. http://www.bioworld.com/articles/732264 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732264-financings-for-july-1-2026 Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of those deals topping $7.5 billion, up 23% from the year-ago semester and just slightly below H1 2024, which saw a total of $7.84 billion in large financings. http://www.bioworld.com/articles/732260 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732260-large-vc-financings-improve-in-h1-2026 Rebound arrows Aptevo Therapeutics Inc. has been awarded a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO-451, Aptevo’s trispecific antibody-like immunotherapy candidate for solid tumors. http://www.bioworld.com/articles/732334 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732334-grant-supports-aptevos-immunotherapy-apvo-451-for-solid-tumors Illustration of cancer cell in crosshairs being destroyed Flare Therapeutics Inc. has closed an $85 million series C financing and completed a strategic review of its pipeline, with funds being channeled to advance the prioritized programs. http://www.bioworld.com/articles/732333 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732333-flare-therapeutics-to-focus-on-ar-on-degrader-fx-111 Telum Therapeutics SL has completed an €18 million (US$24 million) series A financing to advance its lead program targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the multidrug-resistant gram-negative pathogen Acinetobacter baumannii. Acinetobacter baumannii.]]> http://www.bioworld.com/articles/732332 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732332-telum-therapeutics-advances-antimicrobials-with-series-a-funding Euro symbol in piggy bank Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732393 Wed, 01 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732393-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. http://www.bioworld.com/articles/732350 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732350-ollins-330m-series-b-underscores-rise-of-china-origin-newco-model Close-up of a human eye featuring a dollar sign in the iris Biopharma and med-tech companies raising money in public or private financings, including: 4DMT, Akari, Biobot, Neurolife. http://www.bioworld.com/articles/732250 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732250-financings-for-june-30-2026 Smartbax GmbH has announced the successful second closing of its pre-series A financing round for a total of €6.3 million (US$7.2 million) as it advances development of next-generation antibiotics against multidrug-resistant bacteria. http://www.bioworld.com/articles/732311 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732311-smartbax-raises-additional-funds-to-advance-antibiotic-pipeline Illustration of medical professionals, research Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Imagion Biosystems. http://www.bioworld.com/articles/732304 Tue, 30 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/732304-financings-for-june-30-2026 Biopharma and med-tech companies raising money in public or private financings, including: Definium, Idorsia, Imagion, Ligand, Nuvation, Proqr, Uniqure. http://www.bioworld.com/articles/732236 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732236-financings-for-june-29-2026 Biopharma and med-tech companies raising money in public or private financings, including: Grail, Hatch, Helus, Leyden, Lycia, Mesoblast, Optimeos, Pulsenmore, Taysha. http://www.bioworld.com/articles/732179 Fri, 26 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732179-financings-for-june-26-2026 A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic. http://www.bioworld.com/articles/732274 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732274-oblenios-62m-series-b-for-trispecific-antibody-in-autoimmune-diseases Antibodies illustration Biopharma and med-tech companies raising money in public or private financings, including: Anodyne, Calcimedica, Cantargia, Definium, Helus, Moonlake, Osanni, RQ, Uniqure. http://www.bioworld.com/articles/732165 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732165-financings-for-june-25-2026 A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic. http://www.bioworld.com/articles/732161 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732161-oblenios-62m-series-b-for-trispecific-antibody-in-autoimmune-diseases Antibodies illustration The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. http://www.bioworld.com/articles/732160 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732160-ollins-330m-series-b-underscores-rise-of-china-origin-newco-model Close-up of a human eye featuring a dollar sign in the iris RQ Biotechnology Ltd. has completed an oversubscribed $115 million (£85.5 million) series A financing to advance its long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations. http://www.bioworld.com/articles/732130 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732130-series-a-financing-at-rq-bio-to-advance-rqb-01-for-flu-prevention Woman with blanket on couch blowing her nose with a tissue X-tosis Inc. has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support advancement of XTS-001, the lead candidate from the company’s Mitoxts platform, toward clinical development for the treatment of Parkinson’s disease. The grant will support confirmatory studies, biomarker development and IND-enabling work. http://www.bioworld.com/articles/732128 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732128-mjff-grant-to-advance-x-tosis-xts-001-for-parkinsons Female healthcare professional holding dollar sign Biopharma and med-tech companies raising money in public or private financings, including: Kardigan, Ligand, Nicox, Northlinks Bio, Pneumagen, Rapalogix, Trimtech. http://www.bioworld.com/articles/732083 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732083-financings-for-june-24-2026